Novo Nordisk A/S
Novo Alle
Bagsvaerd,
2880
Denmark - Map
Phone: 45 44 44 88 88
Fax: 45 44 49 05 55
Web Site: http://www.novonordisk.com
| Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulin franchise, including modern insulins, human insulins, insulin-related sales, and oral antidiabetic drugs, as well as GLP-1 compounds in development for both the treatment of type 2 diabetes and as an anti-obesity agent. The Biopharmaceuticals segment provides products in the areas of haemostasis management, growth hormone therapy, hormone replacement therapy, inflammation therapy, and other therapy areas. The company sells its products principally in the United States, Japan, China, the Russian Federation, India, Turkey, and other European countries. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Lars Rebien Sorensen , 55
Chief Exec. Officer and Pres |
N/A
| N/A | Mr. Jesper Brandgaard MSc, 47
Chief Financial Officer, Exec. VP, Chairman of Novo Nordisk Engineering A/S and Chairman of Novo Nordisk IT A/S |
N/A
| N/A | Mr. Kåre Schultz , 49
Chief Operating Officer and Exec. VP |
N/A
| N/A | Mr. Kurt Anker Nielsen M.Com., 64
Director, Chairman of Audit Committee and Chief Exec. Officer of Novo A/S |
N/A
| N/A | Dr. Mads Krogsgaard Thomsen Ph.D., 50
Chief Science Officer and Exec. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.50% Nasdaq 
Profile
